US9522127B2 - Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes - Google Patents

Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes Download PDF

Info

Publication number
US9522127B2
US9522127B2 US14/047,391 US201314047391A US9522127B2 US 9522127 B2 US9522127 B2 US 9522127B2 US 201314047391 A US201314047391 A US 201314047391A US 9522127 B2 US9522127 B2 US 9522127B2
Authority
US
United States
Prior art keywords
philadelphia
negative myeloproliferative
syndromes
methyl
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US14/047,391
Other versions
US20140039059A1 (en
Inventor
Tiziano Oldoni
Paolo Mascagni
Alessandro Rambaldi
Tiziano Barbui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Italfarmaco SpA
Original Assignee
Italfarmaco SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Italfarmaco SpA filed Critical Italfarmaco SpA
Priority to US14/047,391 priority Critical patent/US9522127B2/en
Publication of US20140039059A1 publication Critical patent/US20140039059A1/en
Priority to US15/346,926 priority patent/US20170049740A1/en
Application granted granted Critical
Publication of US9522127B2 publication Critical patent/US9522127B2/en
Priority to US17/149,794 priority patent/US20210128512A1/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • Myeloproliferative syndromes are disorders of the neoplastic type which have in common the fact that they originate from pluripotent stem cells from bone marrow, that is to say, cells which, by dividing, can form various types of blood cell.
  • CML chronic myeloid leukaemia
  • PV polycythemia vera
  • ET essential thrombocythemia
  • IM idiopathic myelofibrosis
  • the molecular basis for chronic myeloid leukaemia has been known for some time and consists in the formation of the Philadelphia chromosome, or the 9;22 translocation, and the generation of the BCR-ABL fusion gene; in these cases, called Philadelphia-positive myeloproliferative syndromes, the use of a specific ABL tyrosine kinase inhibitor (such as imitinib or desatinib) makes it possible to intervene selectively in the cells responsible for the pathology, limiting the possible consequences of a non-specific cytotoxicity to the detriment of the healthy cells.
  • a specific ABL tyrosine kinase inhibitor such as imitinib or desatinib
  • Histone deacetylases are enzymes capable of removing the acetyl group bound to the lysine residues in the N-terminal portion of histones or in other proteins.
  • HDACs can be subdivided into four classes, on the basis of structural homologies.
  • Class I HDACs HDAC 1, 2, 3 and 8 are similar to the RPD3 yeast protein and are located in the cell nucleus.
  • Class II HDACs HDAC 4, 5, 6, 7, 9 and 10 are similar to the HDA1 yeast protein and arc located both in the nucleus and in the cytoplasm.
  • Class III HDACs are a structurally distinct form of NAD-dependent enzymes correlated with the SIR2 yeast protein.
  • Class IV (HDAC 11) consists at the moment of a single enzyme having particular structural characteristics.
  • HDACs of classes I, II and IV are zinc enzymes and can be inhibited by various classes of molecule: hydroxamic acid derivatives, cyclic tetrapeptides, short-chain fatty acids, aminobenzamides, derivatives of electrophilic ketones, and the like.
  • Class III HDACs are not inhibited by hydroxamic acids, and their inhibitors have structural characteristics different from those of the other classes.
  • histone deacetylase inhibitor in relation to the present invention is to be understood as meaning any molecule of natural, recombinant or synthetic origin capable of inhibiting the activity of at least one of the enzymes classified as histone deacetylases of class I, class II or class IV.
  • Histone deacetylase inhibitors are a class of molecules provided with anti-neoplastic and anti-inflammatory activity.
  • histone deacetylase inhibitors inhibit cell proliferation and induce cell death and differentiation [Gaofeng Bi and Guosheng Jiang in Cellular & Molecular Immunology 3, 285-290 (2006)].
  • Histone deacetylase inhibitors are also capable of modulating the production of cytokines and other pro-inflammatory factors on the part of immuno-competent cells and have demonstrated, in vivo, anti-inflammatory properties [Frederic Blanchard and Celine Chipoy in Drug Discovery Today 10, 197-204 (2005); IM Adcock in British Journal of Pharmacology 150, 829-831(2007)].
  • a histone deacetylase inhibitor (Zolinza, vorinostat) has been approved for the treatment of cutaneous T-cell lymphoma.
  • histone deacetylase inhibitors currently at the clinical study stage are described, with other analogues thereof, in the following patents: WO 2004/092115, WO 2005/019174, WO 2003/076422, WO 1997/043251, WO 2006/010750, WO 2006/003068, WO 2002/030879, WO 2002/022577, WO 1993/007148, WO 2008/033747, WO 2004/069823, EP 0847992 and WO 2004/071400, the contents of which are incorporated herein by reference in their entirety.
  • ITF2357 reduced by 50% the release of tumor necrosis factor- ⁇ (TNF ⁇ ) at 10 to 22 nM, the release of intracellular interleukin (IL)-1 ⁇ at 12 nM, the secretion of IL-1 ⁇ at 12.5 to 25 nM, and the production of interferon- ⁇ (IFN ⁇ ) at 25 nM.
  • Oral administration of 1.0 to 10 mg/kg ITF2357 to mice reduced LPS-induced serum TNF ⁇ and IFN ⁇ by more than 50% [Flavio Leoni et al. in Molecular Medicine 11, 1-15 (2005)].
  • ITF2357 is capable of inhibiting the clonogenic activity of stem cells obtained from patients suffering from PV or ET [V. Guerini et al. Leukemia 22, 740-747 (2008)].
  • concentrations at which inhibition of clonogenic activity is obtained are much lower than those necessary for obtaining a modification of the molecular markers (JAK2 V617F and STAT proteins) or a cytotoxic effect; the ambiguity of these results makes it difficult to provide for the transferability of these effects, obtained in vitro, to situations of treatment in vivo, especially for any therapeutic treatments in humans.
  • the therapeutic dose of such an active principle, for the treatment of Philadelphia-negative myeloproliferative syndromes in humans is significantly lower than that normally used for the care of tumour syndromes and may be from 10 to 150 mg/day/patient, preferably from 30 to 120 mg/day/patient, and even more preferably from 50 to 100 mg/day/patient.
  • the dose of ZolinzaTM (vorinostat) indicated for the treatment of cutaneous T-cell lymphoma is 400 mg/day.
  • the present invention relates to the use of diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl methyl]-ammonium chloride, preferably in monohydrate form, more preferably in monohydrate crystal form for the therapeutic treatment of Philadelphia-negative myeloproliferative syndromes (polycythemia vera, essential thrombocythemia or idiopathic myelofibrosis).
  • Such an active principle may be used alone, i.e. not in combination with other active principles, or in combination with other cytostatic active principles such as, purely by way of example, hydroxyurea or pipobroman.
  • the present invention relates also to the therapeutic use of such an active principle, for the treatment of Philadelphia-negative myeloproliferative syndromes, at daily doses lower than those used for the treatment of tumour pathologies (for example: cutaneous T-cell lymphoma), these doses being from 10 to 150 mg/day/patient, preferably from 30 to 120 mg/day/patient, and even more preferably from 50 to 100 mg/day/patient.
  • tumour pathologies for example: cutaneous T-cell lymphoma
  • treatment in relation to the present invention, is to be understood as meaning the action of caring for, relieving, mitigating, minimizing, eliminating or blocking the harmful effects resulting from the pathological state or the progression of the disease.
  • the inhibitory activity of a particular compound, with respect to histone deacetylases may be measured in vitro using, for example, an enzyme test which demonstrates the inhibition of at least one of these enzymes. Tests of this type are known in the literature: see, for example, P. A. Marks et al. in J. Natl. Cancer Inst. 92 1210-1215 (2000); L. M. Butler et al. in Cancer Res. 60 5165-5170 (2000); V. M. Richon et al. in Proc. Natl. Acad. Sci . USA 95 3003-3007 (1998); M. Yoshida et al. in J. Biol. Chem. 265 17174-17179 (1990); kits for measuring the HDAC inhibition are also available commercially (e.g. Biomol International LP (USA); HDAC1 Fluorimetric Drug Discovery Kit, product number BML-AK511-0001).
  • Duration of the treatment up to a maximum of 24 weeks of continual administration.
  • the JAK2 V617F mutated, human cell line SET-2 (a megakaryoblastic cell line established from the peripheral blood of a patient with leukemic transformation of essential thrombocythemia) was obtained by the German cell bank DSMZ (catalogue number ACC 608) and grown in 24 well plates in culture medium (RPMI 1640+Hepes buffer 1M+Penicillin 10.000 IU/ml+Streptomycin 10,000 ⁇ g/ml+20% foetal calf serum). Previous experiments were carried out to determine the optimal number of cells giving a sufficient number of clones in each Petri dish to make a reproducible counting. In the case of the SET-2 line the number corresponded to 3 ⁇ 10 3 cells/Petri dish.
  • the cells were harvested by centrifugation (10 min at 10 3 rpm) and then suspended in culture medium at the concentration of 90 ⁇ 10 3 cells/ml. 100 ⁇ l of the suspension were added to 3.0 ml of methyl-cellulose (MethocultTM, catalogue number H4230, Stemcell Technologies) prepared as described by manufacturer and, then, 50 ⁇ l of 63 fold concentrated solution of the HDAC inhibitor in 0.1% DMSO was added. For each compound 5 serial dilutions (1000-12 nM range) were tested. The methyl-cellulose solution containing the HDAC inhibitor was then carefully mixed using a sterile plastic Pasteur pipette avoiding the formation of bubbles.
  • methyl-cellulose Metal-cellulose
  • the EC 50 value (concentration required to reduce of 50% the number of clones) was calculated using GraphPad Prism 5.0 software and reported in the table below. Values for rhHDAC1 inhibition are also reported: the enzyme was obtained from BPS Biosciences (cat n. 50001) and the test was carried out using a BIOMOL kit, according to supplier instructions.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Method of treating Philadelphia-negative myeloproliferative syndromes in a patient suffering from such syndromes. The method is carried out by administering to the patient diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl -methyl]-ammonium chloride, or other pharmaceutically acceptable salts and/or solvates, in a daily dosage amount of from 10 to 150 mg per patient.

Description

This application is a continuation of U.S. patent application Ser. No. 13/064,450 filed Mar. 25, 2011, abandoned, which is a continuation of PCT/EP2009/062214, filed Sep. 21, 2009, which claims priority to Italian Patent Application No. MI2008A001720, filed Sep. 29, 2008 and claims benefit of U.S. Provisional Patent Application No. 61/193,283, filed Nov. 13, 2008, the entire contents of each of which are hereby incorporated by reference.
Myeloproliferative syndromes are disorders of the neoplastic type which have in common the fact that they originate from pluripotent stem cells from bone marrow, that is to say, cells which, by dividing, can form various types of blood cell.
Myeloproliferative syndromes are separated into four types: chronic myeloid leukaemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), and idiopathic myelofibrosis (IM).
The molecular basis for chronic myeloid leukaemia has been known for some time and consists in the formation of the Philadelphia chromosome, or the 9;22 translocation, and the generation of the BCR-ABL fusion gene; in these cases, called Philadelphia-positive myeloproliferative syndromes, the use of a specific ABL tyrosine kinase inhibitor (such as imitinib or desatinib) makes it possible to intervene selectively in the cells responsible for the pathology, limiting the possible consequences of a non-specific cytotoxicity to the detriment of the healthy cells.
For the other three pathologies, grouped under the name of Philadelphia-negative myeloproliferative syndromes, the molecular basis has been identified more recently [see, for example: Robert Kralovics et al. in The New England Journal of Medicine 352, 1779-1790 (2005); Chloé James et al. in Nature 434, 1144-1148 (2005)] and seems to relate to a gene mutation affecting JAK2 tyrosine kinase. For these syndromes, current therapy also provides for the use of cytostatic drugs having a non-specific action, principally hydroxyurea, which present a risk of inducing, after a certain period of treatment, the development of pathologies towards myelodysplastic states and towards forms of leukaemia. In Europe, the incidence of Philadelphia-negative myeloproliferative syndromes is approximately 5 cases for every 100,000 inhabitants per year.
It is therefore clear that it is necessary to identify new drugs which, even for Philadelphia-negative myeloproliferative syndromes (PV, ET and IM), can act in a more selective manner and at non-toxic doses.
Histone deacetylases (HDAC) are enzymes capable of removing the acetyl group bound to the lysine residues in the N-terminal portion of histones or in other proteins.
HDACs can be subdivided into four classes, on the basis of structural homologies. Class I HDACs (HDAC 1, 2, 3 and 8) are similar to the RPD3 yeast protein and are located in the cell nucleus. Class II HDACs (HDAC 4, 5, 6, 7, 9 and 10) are similar to the HDA1 yeast protein and arc located both in the nucleus and in the cytoplasm. Class III HDACs are a structurally distinct form of NAD-dependent enzymes correlated with the SIR2 yeast protein. Class IV (HDAC 11) consists at the moment of a single enzyme having particular structural characteristics. The HDACs of classes I, II and IV are zinc enzymes and can be inhibited by various classes of molecule: hydroxamic acid derivatives, cyclic tetrapeptides, short-chain fatty acids, aminobenzamides, derivatives of electrophilic ketones, and the like. Class III HDACs are not inhibited by hydroxamic acids, and their inhibitors have structural characteristics different from those of the other classes.
The expression “histone deacetylase inhibitor” in relation to the present invention is to be understood as meaning any molecule of natural, recombinant or synthetic origin capable of inhibiting the activity of at least one of the enzymes classified as histone deacetylases of class I, class II or class IV.
Histone deacetylase inhibitors are a class of molecules provided with anti-neoplastic and anti-inflammatory activity.
In tumour cells, histone deacetylase inhibitors inhibit cell proliferation and induce cell death and differentiation [Gaofeng Bi and Guosheng Jiang in Cellular & Molecular Immunology 3, 285-290 (2006)].
Histone deacetylase inhibitors are also capable of modulating the production of cytokines and other pro-inflammatory factors on the part of immuno-competent cells and have demonstrated, in vivo, anti-inflammatory properties [Frederic Blanchard and Celine Chipoy in Drug Discovery Today 10, 197-204 (2005); IM Adcock in British Journal of Pharmacology 150, 829-831(2007)].
Numerous clinical studies, both on tumour pathologies and on inflammatory pathologies, are currently underway, and are at various stages of advance, using various inhibitors [Marielle Paris et al., in Journal of Medicinal Chemistry 51, 1505-1529 (2008)].
Recently, a histone deacetylase inhibitor (Zolinza, vorinostat) has been approved for the treatment of cutaneous T-cell lymphoma.
Some of the histone deacetylase inhibitors currently at the clinical study stage are described, with other analogues thereof, in the following patents: WO 2004/092115, WO 2005/019174, WO 2003/076422, WO 1997/043251, WO 2006/010750, WO 2006/003068, WO 2002/030879, WO 2002/022577, WO 1993/007148, WO 2008/033747, WO 2004/069823, EP 0847992 and WO 2004/071400, the contents of which are incorporated herein by reference in their entirety.
Diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl methyl]-ammonium chloride, which is described in WO 97/43251 (anhydrous form) and in WO 2004/065355 (monohydrate crystal form), herein both incorporated by reference, is an HDAC inhibitor with good anti-inflammatory activities; such an active principle is also known as ITF2357 and/or Givinostat. In lipopolysaccharide (LPS)-stimulated cultured human peripheral blood mononuclear cells (PBMCs), ITF2357 reduced by 50% the release of tumor necrosis factor-α (TNFα) at 10 to 22 nM, the release of intracellular interleukin (IL)-1α at 12 nM, the secretion of IL-1β at 12.5 to 25 nM, and the production of interferon-γ (IFNγ) at 25 nM. Oral administration of 1.0 to 10 mg/kg ITF2357 to mice reduced LPS-induced serum TNFα and IFNγ by more than 50% [Flavio Leoni et al. in Molecular Medicine 11, 1-15 (2005)].
It has recently been reported that ITF2357, at sub-micromolar concentrations, is capable of inhibiting the clonogenic activity of stem cells obtained from patients suffering from PV or ET [V. Guerini et al. Leukemia 22, 740-747 (2008)]. However, the concentrations at which inhibition of clonogenic activity is obtained are much lower than those necessary for obtaining a modification of the molecular markers (JAK2V617F and STAT proteins) or a cytotoxic effect; the ambiguity of these results makes it difficult to provide for the transferability of these effects, obtained in vitro, to situations of treatment in vivo, especially for any therapeutic treatments in humans.
DESCRIPTION OF THE INVENTION
We have now found, and this constitutes one aspect of the present invention, that the administration of diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl methyl]-ammonium chloride, preferably in monohydrate form, more preferably in monohydrate crystal form, to patients suffering from polycythemia vera, essential thrombocythemia or myelo fibrosis causes a complete or partial response; in addition, in patients who initally demonstrated a state of splenomegaly, a significant reduction in the volume of the spleen is observed.
We have also found, and this constitutes a second aspect of the invention, that the therapeutic dose of such an active principle, for the treatment of Philadelphia-negative myeloproliferative syndromes in humans, is significantly lower than that normally used for the care of tumour syndromes and may be from 10 to 150 mg/day/patient, preferably from 30 to 120 mg/day/patient, and even more preferably from 50 to 100 mg/day/patient.
Purely by way of example, the dose of Zolinza™ (vorinostat) indicated for the treatment of cutaneous T-cell lymphoma is 400 mg/day.
The present invention relates to the use of diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl methyl]-ammonium chloride, preferably in monohydrate form, more preferably in monohydrate crystal form for the therapeutic treatment of Philadelphia-negative myeloproliferative syndromes (polycythemia vera, essential thrombocythemia or idiopathic myelofibrosis). Such an active principle may be used alone, i.e. not in combination with other active principles, or in combination with other cytostatic active principles such as, purely by way of example, hydroxyurea or pipobroman.
The present invention relates also to the therapeutic use of such an active principle, for the treatment of Philadelphia-negative myeloproliferative syndromes, at daily doses lower than those used for the treatment of tumour pathologies (for example: cutaneous T-cell lymphoma), these doses being from 10 to 150 mg/day/patient, preferably from 30 to 120 mg/day/patient, and even more preferably from 50 to 100 mg/day/patient.
The term “treatment”, in relation to the present invention, is to be understood as meaning the action of caring for, relieving, mitigating, minimizing, eliminating or blocking the harmful effects resulting from the pathological state or the progression of the disease.
The inhibitory activity of a particular compound, with respect to histone deacetylases, may be measured in vitro using, for example, an enzyme test which demonstrates the inhibition of at least one of these enzymes. Tests of this type are known in the literature: see, for example, P. A. Marks et al. in J. Natl. Cancer Inst. 92 1210-1215 (2000); L. M. Butler et al. in Cancer Res. 60 5165-5170 (2000); V. M. Richon et al. in Proc. Natl. Acad. Sci. USA 95 3003-3007 (1998); M. Yoshida et al. in J. Biol. Chem. 265 17174-17179 (1990); kits for measuring the HDAC inhibition are also available commercially (e.g. Biomol International LP (USA); HDAC1 Fluorimetric Drug Discovery Kit, product number BML-AK511-0001).
The following examples are intended to be illustrative of the invention rather than limiting the scope thereof.
EXAMPLE 1
Clinical study of ITF2357 in patients suffering from Philadelphia-negative myeloproliferative syndromes. Design: phase II, open, non-randomized study. Population in the study: 27 patients with the JAK2V617F mutation suffering from myeloproliferative syndromes not adequately controlled by the standard pharmacological treatment (hydroxyurea).
Drug under study: ITF2357 at a dose of 50 mg twice per day.
Duration of the treatment: up to a maximum of 24 weeks of continual administration.
Primary objective: to evaluate the efficiency and tolerability of ITF2357 in the treatment of patients having JAK2V617F-positive myeloproliferative diseases (PV, ET, IM).
Secondary objective: to evaluate the effect of the treatment on the mutated JAK2 allele burden by quantitative PCR.
Examination of the preliminary data (duration of the treatment from 4 to 12 weeks) shows that the administration of ITF2357 to patients suffering from polycythemia vera, essential thrombocythemia or myelofibrosis induces a complete or partial response in approximately 60% of cases; in addition, a significant reduction in the volume of the spleen is observed in patients who initially exhibited a state of splenomegaly.
EXAMPLE 2 Comparative Effect on the Cloning Efficiency of the Human Cell Line SET-2
The JAK2V617F mutated, human cell line SET-2 (a megakaryoblastic cell line established from the peripheral blood of a patient with leukemic transformation of essential thrombocythemia) was obtained by the German cell bank DSMZ (catalogue number ACC 608) and grown in 24 well plates in culture medium (RPMI 1640+Hepes buffer 1M+Penicillin 10.000 IU/ml+Streptomycin 10,000 μg/ml+20% foetal calf serum). Previous experiments were carried out to determine the optimal number of cells giving a sufficient number of clones in each Petri dish to make a reproducible counting. In the case of the SET-2 line the number corresponded to 3×103 cells/Petri dish. When a sufficient number of cells were obtained, the cells were harvested by centrifugation (10 min at 103 rpm) and then suspended in culture medium at the concentration of 90×103 cells/ml. 100 μl of the suspension were added to 3.0 ml of methyl-cellulose (Methocult™, catalogue number H4230, Stemcell Technologies) prepared as described by manufacturer and, then, 50 μl of 63 fold concentrated solution of the HDAC inhibitor in 0.1% DMSO was added. For each compound 5 serial dilutions (1000-12 nM range) were tested. The methyl-cellulose solution containing the HDAC inhibitor was then carefully mixed using a sterile plastic Pasteur pipette avoiding the formation of bubbles. At the end 1 ml of the solution was homogeneously dispensed in a Petri dish (35 mm diameter with grid, catalogue number 174926 Nunc) using a syringe with a 18G needle. For each experimental point 2 Petri dishes were done. The 2 experimental dishes were put in an larger Petri dish along with a reservoir of sterile water to ensure a constant humidity. All the dishes were then maintained at 37° C. in a humidity and CO2-controlled sterile incubator. After 14 days of growing the number of clones in each dish was determined by using a binocular microscope. The average number of clones for each coupe of dishes was calculated and the percentage inhibition of clones formation was determined in respect to the number of clones obtained in the absence of any compounds (control dishes). The EC50 value (concentration required to reduce of 50% the number of clones) was calculated using GraphPad Prism 5.0 software and reported in the table below. Values for rhHDAC1 inhibition are also reported: the enzyme was obtained from BPS Biosciences (cat n. 50001) and the test was carried out using a BIOMOL kit, according to supplier instructions.
TABLE 1
IC50 nM
Code Originator INN Chemical Class EC50 μM (rhHDACl)
ITF2357 Italfarmaco Givinostat Hydroxamic acid 0.028-0.054* 121
MGCD-0103 MethylGene Mocetinostat Benzamide 1.196** 17
KD-5170 Kalypsys — S,Acetyl-α-mercaptoketone <20% inhib. 24
at 1 μM
SNDX-275 Bayer Schering Entinostat Benzamide 1.820** 293
*values obtained in two different experiment
**p < 0.05 towards ITF2357 in the same experiment
Although Mocetinostat and Entinostat are considered as class I specific HDAC inhibitors [Zhou, N. et al. J Med Chem 51, 4072 (2008) and Jones, P. et al. J Med Chem 51, 2350 (2008)], KD-5170 has been reported to be a broad spectrum Class I and II-HDAC inhibitor [WO 2007/067795; Payne, J. E. et al. Bioorg Med Chem Lett 18, 6093 (2008)], the same as ITF2357.
Although, the inhibition of cloning efficiency of SET-2 cells is not proven to be predictive for the cure of the Philadelphia-negative, JAK2V617F-positive, myeloproliferative syndromes, the potent inhibitory effect of ITF2357, if compared to the other HDAC inhibitors, seems to indicate that the presence of histone deacetylase inhibition is not essential for obtaining the clinical efficacy shown by ITF2357 with respect to Philadelphia-negative myeloproliferative syndromes.
The tested compounds correspond to the following formulae:
Figure US09522127-20161220-C00001

Claims (9)

The invention claimed is:
1. Method of treating Philadelphia-negative myeloproliferative syndromes in a patient suffering from said syndromes, said method comprising administering to said patient diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride, or other pharmaceutically acceptable salts and/or solvates, and at least one other cytostatic active principle, wherein said diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride, or other pharmaceutically acceptable salts and/or solvates thereof is administered in a daily dosage amount of from 50 to 150 mg per patient.
2. Method according to claim 1, wherein said diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride is in monohydrate form.
3. Method according to claim 1, wherein said diethyl[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride is in monohydrate crystal form.
4. Method according to claim 1, wherein said Philadelphia-negative myeloproliferative syndrome is polycythemia vera.
5. Method according to claim 1, wherein said Philadelphia-negative myeloproliferative syndrome is essential thrombocythemia.
6. Method according to claim 1, wherein said Philadelphia-negative myeloproliferative syndrome is primary myeofibrosis.
7. Method according to claim 1, wherein said Philadelphia-negative myeloproliferative syndrome is secondary myelofibrosis.
8. Method according to claim 1, wherein said at least one other cytostatic active principle is selected from the group consisting of hydroxyurea and pipobroman.
9. Method according to claim 1, wherein said daily dosage is from 50 to 100 mg per patient.
US14/047,391 2008-09-29 2013-10-07 Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes Active 2029-10-06 US9522127B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US14/047,391 US9522127B2 (en) 2008-09-29 2013-10-07 Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes
US15/346,926 US20170049740A1 (en) 2008-09-29 2016-11-09 Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes
US17/149,794 US20210128512A1 (en) 2008-09-29 2021-01-15 Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
ITMI2008A001720 2008-09-29
ITMI2008A001720A IT1392908B1 (en) 2008-09-29 2008-09-29 USE OF HISTONE-DEACETYLASE INHIBITORS FOR PHILADELPHIA-NEGATIVE CARE OF MYELOPROLIFERATIVE SYNDROMES
US19328308P 2008-11-13 2008-11-13
PCT/EP2009/062214 WO2010034693A1 (en) 2008-09-29 2009-09-21 Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes
US13/064,450 US20110294892A1 (en) 2008-09-29 2011-03-25 Use of histone deacetylase inhibitors for the care of Philadephia-negative myeloproliferative syndromes
US14/047,391 US9522127B2 (en) 2008-09-29 2013-10-07 Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US13/064,450 Division US20110294892A1 (en) 2008-09-29 2011-03-25 Use of histone deacetylase inhibitors for the care of Philadephia-negative myeloproliferative syndromes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/346,926 Continuation US20170049740A1 (en) 2008-09-29 2016-11-09 Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes

Publications (2)

Publication Number Publication Date
US20140039059A1 US20140039059A1 (en) 2014-02-06
US9522127B2 true US9522127B2 (en) 2016-12-20

Family

ID=40810309

Family Applications (4)

Application Number Title Priority Date Filing Date
US13/064,450 Abandoned US20110294892A1 (en) 2008-09-29 2011-03-25 Use of histone deacetylase inhibitors for the care of Philadephia-negative myeloproliferative syndromes
US14/047,391 Active 2029-10-06 US9522127B2 (en) 2008-09-29 2013-10-07 Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes
US15/346,926 Abandoned US20170049740A1 (en) 2008-09-29 2016-11-09 Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes
US17/149,794 Pending US20210128512A1 (en) 2008-09-29 2021-01-15 Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US13/064,450 Abandoned US20110294892A1 (en) 2008-09-29 2011-03-25 Use of histone deacetylase inhibitors for the care of Philadephia-negative myeloproliferative syndromes

Family Applications After (2)

Application Number Title Priority Date Filing Date
US15/346,926 Abandoned US20170049740A1 (en) 2008-09-29 2016-11-09 Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes
US17/149,794 Pending US20210128512A1 (en) 2008-09-29 2021-01-15 Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes

Country Status (17)

Country Link
US (4) US20110294892A1 (en)
EP (1) EP2344253B1 (en)
JP (1) JP2012504112A (en)
KR (3) KR20110069075A (en)
CN (1) CN102164638A (en)
BR (1) BRPI0913699A2 (en)
CA (1) CA2738081C (en)
CY (1) CY1115255T1 (en)
DK (1) DK2344253T3 (en)
ES (1) ES2478827T3 (en)
HR (1) HRP20140499T1 (en)
IT (1) IT1392908B1 (en)
PL (1) PL2344253T3 (en)
PT (1) PT2344253E (en)
SI (1) SI2344253T1 (en)
SM (1) SMT201400087B (en)
WO (1) WO2010034693A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8217079B2 (en) * 2010-03-26 2012-07-10 Italfarmaco Spa Method for treating Philadelphia-negative myeloproliferative syndromes
WO2015165975A1 (en) * 2014-04-29 2015-11-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating myeloid neoplasias
TW201821105A (en) 2016-10-20 2018-06-16 美商弗瑪治療公司 Method of using HDAC11 inhibitor
EP3583155B1 (en) * 2017-02-20 2024-05-08 Dow Silicones Corporation Room-temperature-curable silicone composition and electric/electronic apparatus
US11535607B2 (en) 2018-04-20 2022-12-27 Valo Health, Inc. Isoindolines as HDAC inhibitors

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993007148A1 (en) 1991-10-04 1993-04-15 Sloan-Kettering Institute For Cancer Research Novel potent inducers of terminal differentiation and methods of use thereof
WO1997043251A1 (en) 1996-05-14 1997-11-20 Italfarmaco S.P.A. Compounds with anti-inflammatory and immunosuppressive activities
EP0847992A1 (en) 1996-09-30 1998-06-17 Mitsui Chemicals, Inc. Benzamide derivatives, useful as cell differentiation inducers
WO2004065355A1 (en) 2003-01-17 2004-08-05 Italfarmaco Spa Monohydrate hydrochloride of the 4-hydroxycarbamoyl-phenyl)-carbamic acid (6-diethylaminomethyl-naphtalen-2-yl) ester
WO2004071400A2 (en) 2003-02-14 2004-08-26 Shenzhen Chipscreen Biosciences Ltd. Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
WO2006063294A2 (en) 2004-12-09 2006-06-15 Kalypsys, Inc. Novel inhibitors of histone deacetylase for the treatment of disease
WO2007016354A1 (en) 2005-07-29 2007-02-08 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
WO2007067795A2 (en) 2005-12-09 2007-06-14 Massachusetts Institute Of Technology Methods for identifying and targeting tumor stem cells based on nuclear morphology
WO2008058287A1 (en) 2006-11-10 2008-05-15 Syndax Pharmaceuticals, Inc. COMBINATION OF ERα+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER
WO2008082646A2 (en) 2006-12-28 2008-07-10 The Johns Hopkins University Histone deacetylase inhibitors, combination therapies and methods of use
US20090088410A1 (en) 2002-11-06 2009-04-02 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20030064A1 (en) * 2003-01-17 2004-07-18 Italfarmaco Spa USE OF HYDROXAMIC ACID DERIVATIVES FOR PREPARATION

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993007148A1 (en) 1991-10-04 1993-04-15 Sloan-Kettering Institute For Cancer Research Novel potent inducers of terminal differentiation and methods of use thereof
WO1997043251A1 (en) 1996-05-14 1997-11-20 Italfarmaco S.P.A. Compounds with anti-inflammatory and immunosuppressive activities
EP0847992A1 (en) 1996-09-30 1998-06-17 Mitsui Chemicals, Inc. Benzamide derivatives, useful as cell differentiation inducers
US20090088410A1 (en) 2002-11-06 2009-04-02 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
WO2004065355A1 (en) 2003-01-17 2004-08-05 Italfarmaco Spa Monohydrate hydrochloride of the 4-hydroxycarbamoyl-phenyl)-carbamic acid (6-diethylaminomethyl-naphtalen-2-yl) ester
WO2004071400A2 (en) 2003-02-14 2004-08-26 Shenzhen Chipscreen Biosciences Ltd. Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
WO2006063294A2 (en) 2004-12-09 2006-06-15 Kalypsys, Inc. Novel inhibitors of histone deacetylase for the treatment of disease
WO2007016354A1 (en) 2005-07-29 2007-02-08 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
WO2007067795A2 (en) 2005-12-09 2007-06-14 Massachusetts Institute Of Technology Methods for identifying and targeting tumor stem cells based on nuclear morphology
WO2008058287A1 (en) 2006-11-10 2008-05-15 Syndax Pharmaceuticals, Inc. COMBINATION OF ERα+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER
WO2008082646A2 (en) 2006-12-28 2008-07-10 The Johns Hopkins University Histone deacetylase inhibitors, combination therapies and methods of use

Non-Patent Citations (33)

* Cited by examiner, † Cited by third party
Title
Adcock, Im; "HDAC inhibitors as anti-inflammatory agents"; British Journal of Pharmacology, vol. 150, pp. 829-831 (2007).
Barosi, G., et al; "Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference"; Blood, vol. 113; pp. 4829-4833 (2009).
Berk, P.D., et al; "Increase Incidence of Acute Leukemia in Polycythemia Vera Associated with Chlorambucil Therapy"; The New England Journal of Medicine, vol. 304, No. 8, pp. 441-447 (1981).
Bi, G., et al; "The Molecular Mechanism of HDAC Inhibitors in Anticancer Effects"; Cellular & Molecular Immunology, vol. 3, No. 4, pp. 285-290 (2006).
Blanchard, F., et al; "Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?"; Drug Discovery Today, vol. 10, No. 3, pp. 197-204 (2005).
Bonfante, V., et al; "Phase II Study of the Histone-Deacetylase Inhibitor ITF2357 in Relapsed/Refradtory Hodgkin's Lymphoma Patients"; Haematologica, vol. 93(s1), p. 244, XP008160204 (2008).
Butler, L.M., et al; "Suberoylanilide Hydroxamic Acid, an Inhibitor of Histone Deacetylase, Suppresses the Growth of Prostate Cancer Cells in Vitro and in Vivo1"; Cancer Research, vol. 60, pp. 5165-5170 (2000).
Fathallah, H., et al; "Induction of Fetal Hemoglobin in the Treatment of Sickle Cell Disease"; American Society of Hematology, pp. 58-62 (2006).
Galli, Monica, et al; "A phase II multiple dose clinical trial of historic deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma: Preliminary results"; Blood, vol. 110, No. 11, Part 1, pp. 356A (2007) STN 2008:216406 BIOSIS.
Golay et al. "The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vito and inhibits IL-6 and VEGF production by stromal cells" Leukemia, 2007, vol. 21, pp. 1892-1900. *
Guerini, V., et al; "The histone deace6tylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2V617F"; Leukemia, vol. 22, No. 4, pp. 740-747 (2008) XP008114983.
Guerini, V., et al; "The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2V617F"; Leukemia, pp. 1-8 (2007).
Guerini, V., et al; 12th Congress of the European Hematology Association, Jun. 7-10, 2007; "Potent and Selective Inhibition of EEC Colony Formation in JAK2V617F Polycythemia Vera and Thrombocythemia by Low Doses of ITF2357, A New Histone Deacetylase Inhibitor"; Heamatologica 2007; [suppl. 2]:89, Abstract 0245; http://online.haematologica.org/eha12/browserecord-prt.php?-action=browse&-recid, p. 1 of 1; dated Apr. 2, 2016.
Guerini, Vittoria, et al; "Potent inhibition of EEC Colony Formation in JAK2V617F PV and ET by Low Doses of ITF2357, a New Histone Deacetylase Inhibitor"; Blood, (ASH Annual Meeting Abstracts), vol. 108, No. 11, Part 1, 3 pgs. (2006).
Guerini, Vittoria, et al; "Selective Targeting of the JAK2V617F Mutation in Polycythemia Vera and Essential Thrombocythemia by ITF2357, a Novel Histone Deacetylase Inhibitior"; Blood, vol. 110, No. 11, Part 1, 3 pgs. (2007).
James, C., et al; "A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera"; Nature, vol. 34, pp. 1144-1148 (2005).
Johansson, P., et al; "The effects of hydroxyurea on PRV-1 expression in patients with essential thrombocythemia and polychtmia vera"; Haematologica, vol. 89, No. 10, pp. 1264-1266 (2004).
Jones, P., et al; "A Novel Series of Potent and Selective Ketone Histone Deacetylase Inhibitors with Antitumor Activity in Vivo"; J. Med. Chem., vol. 51, pp. 2350-2353 (2008).
Kralovics, R., et al; "A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders"; The New England Journal of Medicine, vol. 352, pp. 1779-90 (2005).
Leoni, F., et al; "The Histone Deacetylase Inhibitor ITF2357 Reduces Production of Pro-Inflammatory Cytokines in Vitro and Systemic Inflammation in Vivo"; Molecular Medicine, vol. 11, No. 1-12, pp. 1-15 (2005).
Marks, P.A., et al; "Histone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells"; Journal of the National Cancer Institute, vol. 92, No. 15, pp. 1210-1215 (2000).
Martin, et al; "HEL Cells: A New Human Erythroleukemia Cell Line with Spontaneous and Induced Globin Expression"; Science, vol. 216, pp. 1233-1235, XP008160201 (1982).
Mesa, et al; "Bortezomib therapy in myelofibrosis: a phase II clinical trial"; Leukemia, vol. 22, pp. 1636-1638 (2008).
Najean, Y., et al; "Treatment of Polycythemia Vera: The Use of Hydroxyurea and Pipobroman in 292 Patients Under the Age of 65 Years"; Blood, vol. 90, p. 3370-3377 (1997).
Paris, M., et al; "Histone Deacetylase Inhibitors: From Bench to Clinic"; Journal of Medicinal Chemistry; vol. 51, No. 6, pp. 1505-1529 (2008).
Prchal, J.T.; "Philadelphia Chromosome-Negative Myeloproliferative Disorders: An Historical Perspective"; American Society of Hematology, p. 68 (Jan. 1, 2008).
Quintas-Cardama, A., et al; "A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis"; Leukemia, vol. 22, pp. 965-970 (2008).
Richon, V.M., et al; "A class of hydrib polar inducers of transformed cell differentiation inhibits histone deacetylases"; Proc. Natl. Acad. Sci., vol. 95, pp. 3003-3007 (1998).
Silver, R.T.; "Treatment of Polycythemia Vera"; Seminars in Thrombosis and Hemostasis, vol. 32, No. 4, pp. 437-442 (2006).
Tutaeva, V., et al; "Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea"; Hematology, vol. 12, No. 6, pp. 473-479 (2007).
Uozumi, K., et al; "Establishment and characterization of a new human megakaryoblastic cell line (SET-2) that spontaneously matures to megakaryocytes and produces platelet-like particles"; Leukemia, vol. 14, pp. 142-152 (2000).
Vojinovic, J., et al; "Presentation: Safety and Efficacy of Oral ITF 2357 in Patients with Active Systemic Onset Juvenile Idiopathic Arthritis (SOJIA)-Results of a Phase II, Open Label, International, Multicentre Clinical Trial"; American College of Rheumatology, 2008 Annual Scientific Meeting; 1 pg, XP008160205 (2008).
Yoshida, M., et al; "Potent and Specific Inhibition of Mammalian Histone Deacetylase Both in Vivo and in Vitro by Trichostatin A*"; The Journal of Biological Chemistry; vol. 265, No. 28, pp. 17174-17179 (1990).

Also Published As

Publication number Publication date
KR20160096721A (en) 2016-08-16
PL2344253T3 (en) 2014-09-30
EP2344253B1 (en) 2014-04-23
SMT201400087B (en) 2014-09-08
ITMI20081720A1 (en) 2010-03-30
KR20170124640A (en) 2017-11-10
WO2010034693A1 (en) 2010-04-01
CA2738081A1 (en) 2010-04-01
CN102164638A (en) 2011-08-24
US20110294892A1 (en) 2011-12-01
SI2344253T1 (en) 2014-08-29
JP2012504112A (en) 2012-02-16
US20210128512A1 (en) 2021-05-06
KR20110069075A (en) 2011-06-22
BRPI0913699A2 (en) 2017-06-13
US20170049740A1 (en) 2017-02-23
US20140039059A1 (en) 2014-02-06
CA2738081C (en) 2017-11-07
IT1392908B1 (en) 2012-04-02
PT2344253E (en) 2014-07-16
EP2344253A1 (en) 2011-07-20
HRP20140499T1 (en) 2014-07-04
CY1115255T1 (en) 2017-01-04
DK2344253T3 (en) 2014-06-16
ES2478827T3 (en) 2014-07-23

Similar Documents

Publication Publication Date Title
US20210128512A1 (en) Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes
KR100518106B1 (en) Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies
JP2005525345A (en) Methods for treating TRX-mediated diseases
US20100216755A1 (en) Anti-tumor agent
AU2018392985A1 (en) Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
Furuya et al. Treatment of rat spinal cord injury with a Rho-kinase inhibitor and bone marrow stromal cell transplantation
KR20200015735A (en) Compositions and Methods for Preventing or Treating Muscle Diseases
RU2768120C2 (en) Method for treating multiple sclerosis using lsd1 inhibitor
ES2985012T3 (en) Coadministration of mirdametinib and lifirafenib for use in the treatment of cancer
WO2009155777A1 (en) The use and method of the compound of fasudil and the pharmaceutical composition thereof
Pan et al. Holomycin, a novel NLRP3 inhibitor, attenuates cartilage degeneration and inflammation in osteoarthritis
US8217079B2 (en) Method for treating Philadelphia-negative myeloproliferative syndromes
KR102174191B1 (en) Bisamide derivatives of dicarboxylic acids as agents for stimulating tissue regeneration and restoration of reduced tissue function
US10220019B2 (en) Method for treating pulmonary fibrosis comprising application of dimethylamino micheliolide
JP2009504751A (en) Topical preparation of histone deacetylase inhibitor and method of use thereof
CN113244233A (en) Application of piperlongumine in preparation of medicine for preventing and treating corneal transplantation immunological rejection
KR20210056931A (en) Pharmaceutical composition for treatment or prevention of immune-related diseases comprising pyrimethamine as an active ingredient
US20210386744A1 (en) Sildenafil for use in the treatment of osteoarthritis
US20110046223A1 (en) Treatment of neurofibromatosis
CN114366738A (en) Use of rapamycin in promoting neural stem cell expansion
WO2018006689A1 (en) Use of fulvestrant in preparation of medicament for treating nonfunctioning pituitary adenoma
CN118576597A (en) A combined pharmaceutical composition and its use in preparing a drug for preventing, improving or treating TP53 mutation double-hit lymphoma
JP2005213159A (en) Neovascularization inhibitor and vascular retraction agent
Guo et al. Mechanism of Activation of AMPK/P53-CyPD Signalling Pathway in Inhibiting Osteoblast Apoptosis Induced by Dexamethasone.
CN120154719A (en) Application of BCL2 inhibitors in the treatment of giant congenital nevus

Legal Events

Date Code Title Description
STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8